Literature DB >> 21138765

Truncated forms of BNIP3 act as dominant negatives inhibiting hypoxia-induced cell death.

Nicolle Bristow1, Teralee R Burton, Elizabeth S Henson, Coleen Ong-Justiniano, Michelle Brown, Spencer B Gibson.   

Abstract

BNIP3 (Bcl-2/adenovirus E1B Nineteen Kilodalton Interacting Protein) is a pro-cell death member of the Bcl-2 family of proteins. Its expression is induced by the transcription factor Hypoxia Inducible Factor-1 (HIF-1) under conditions of low oxygen (hypoxia) and is found over expressed in hypoxic regions of many tumors. When over expressed, BNIP3 induces cell death through induction of mitochondrial dysfunction that is dependent on the presence of BNIP3's TM domain. Herein, we have determined that the SkOv3 ovarian cancer cell line expresses a truncated BNIP3 protein, which results in the elimination of the transmembrane domain. Truncation that eliminates all four domains of BNIP3 protein also inhibits hypoxia-induced cell death in SkOv3, HEK293, U251 and MCF-7 cells. Three different mutations in a BNIP3 expression vector that lead to a truncated BNIP3 protein, lacking TM domain only, or lacking CD, BH3, and TM domains resulted in inhibition of hypoxia-induced cell death when transfected into HEK293 cells. We found that truncated BNIP3 failed to associate with the mitochondria and the truncated BNIP3 lacking all four domains can bind to wild type BNIP3. Taken together, truncation of BNIP3 could be a novel mechanism for cancer cells to avoid hypoxia-induced cell death mediated by BNIP3 over expression. Copyright Â
© 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21138765      PMCID: PMC3164856          DOI: 10.1016/j.bbadis.2010.11.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  34 in total

Review 1.  BNips: a group of pro-apoptotic proteins in the Bcl-2 family.

Authors:  H M Zhang; P Cheung; B Yanagawa; B M McManus; D C Yang
Journal:  Apoptosis       Date:  2003-06       Impact factor: 4.677

Review 2.  BNip3 and signal-specific programmed death in the heart.

Authors:  Keith A Webster; Regina M Graham; Nanette H Bishopric
Journal:  J Mol Cell Cardiol       Date:  2004-12-13       Impact factor: 5.000

3.  The Bcl-2 family pro-apoptotic molecule, BNIP3 regulates activation-induced cell death of effector cytotoxic T lymphocytes.

Authors:  J Wan; D Martinvalet; X Ji; C Lois; S M Kaech; U H Von Andrian; J Lieberman; R Ahmed; N Manjunath
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

Review 4.  Importance of hypoxia in the biology and treatment of brain tumors.

Authors:  Jonathan P S Knisely; Sara Rockwell
Journal:  Neuroimaging Clin N Am       Date:  2002-11       Impact factor: 2.264

5.  BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites.

Authors:  R Ray; G Chen; C Vande Velde; J Cizeau; J H Park; J C Reed; R D Gietz; A H Greenberg
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

6.  The C. elegans orthologue ceBNIP3 interacts with CED-9 and CED-3 but kills through a BH3- and caspase-independent mechanism.

Authors:  J Cizeau; R Ray; G Chen; R D Gietz; A H Greenberg
Journal:  Oncogene       Date:  2000-11-16       Impact factor: 9.867

7.  The carboxy terminal C-tail of BNip3 is crucial in induction of mitochondrial permeability transition in isolated mitochondria.

Authors:  Jee-Yeon Kim; Jeong-Je Cho; Joohun Ha; Jae-Hoon Park
Journal:  Arch Biochem Biophys       Date:  2002-02-15       Impact factor: 4.013

8.  Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes.

Authors:  Kelly M Regula; Karen Ens; Lorrie A Kirshenbaum
Journal:  Circ Res       Date:  2002-08-09       Impact factor: 17.367

9.  BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF.

Authors:  Shilpa Kothari; Jeannick Cizeau; Eileen McMillan-Ward; Sara J Israels; Michelle Bailes; Karen Ens; Lorrie A Kirshenbaum; Spencer B Gibson
Journal:  Oncogene       Date:  2003-07-24       Impact factor: 9.867

Review 10.  Hypoxia and tumor response to irradiation.

Authors:  Gian Luca Sannazzari; Umberto Ricardi; Andrea R Filippi
Journal:  Rays       Date:  2002 Jul-Sep
View more
  6 in total

1.  Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3.

Authors:  Feiyan Liu; Qianqian Liu; Dafeng Yang; Wendy B Bollag; Keith Robertson; Ping Wu; Kebin Liu
Journal:  Cancer Res       Date:  2011-09-12       Impact factor: 12.701

2.  Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells.

Authors:  Yongqiang Chen; Elizabeth S Henson; Wenyan Xiao; Epsita Shome; Meghan B Azad; Teralee R Burton; Michelle Queau; Akshay Sathya; David D Eisenstat; Spencer B Gibson
Journal:  Cancer Biol Ther       Date:  2015-10-15       Impact factor: 4.742

3.  p53 directly suppresses BNIP3 expression to protect against hypoxia-induced cell death.

Authors:  Xi Feng; Xing Liu; Wei Zhang; Wuhan Xiao
Journal:  EMBO J       Date:  2011-07-26       Impact factor: 11.598

4.  Phosphorylation of the BNIP3 C-Terminus Inhibits Mitochondrial Damage and Cell Death without Blocking Autophagy.

Authors:  Katherine E Liu; William A Frazier
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

5.  Metabolic phenotypes in pancreatic cancer.

Authors:  Min Yu; Quanbo Zhou; Yu Zhou; Zhiqiang Fu; Langping Tan; Xiao Ye; Bing Zeng; Wenchao Gao; Jiajia Zhou; Yimin Liu; Zhihua Li; Ye Lin; Qing Lin; Rufu Chen
Journal:  PLoS One       Date:  2015-02-26       Impact factor: 3.240

6.  BNIP3 contributes to cisplatin-induced apoptosis in ovarian cancer cells.

Authors:  Jinghui Jia; Xiaoxin Yang; Qing Zhao; Feiquan Ying; E Cai; Si Sun; Xiaoqi He
Journal:  FEBS Open Bio       Date:  2020-06-27       Impact factor: 2.693

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.